The Indian government has given permission for human testing of the first indigenous Covid-19 vaccine. The vaccine called 'Covaxin' is being developed by Bharat Biotech. Bharat Biotech has developed the vaccine in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). In a statement issued by the organisation, it has been said that human trials have been approved by the Drug Controller General of India (DCGI).
Drug manufacturers around the world are engaged in an effort to develop a vaccine against the deadly coronavirus. Leading manufacturer of vaccines and generic drugs, India is expected to play an important role in this race, with many institutes working with different drugs. Recently, it was said on behalf of the government that 30 groups are engaged in the work of making the vaccine.
Bharat Krishna Biotech Chairman and MD, said, "We are proud to announce Covaxin, India's first indigenous vaccine for Covid-19. The collaboration of ICMR and NIV in preparing it was remarkable. The positive attitude of CDSCO was helpful in getting its testing approved. Efforts are underway all over the world to prepare the Covid-19 vaccine. No one has been successful yet. However, some companies have reached the stage of human testing".
Many companies around the world are also engaged in the same. Last week, the World Health Organization (WHO) said that Britain's AstraZeneca is very close to preparing the vaccine. Researchers at the University of Oxford are working on this vaccine.
It is important to note that the coronavirus in India continues to wreak havoc, as the cases increase everyday. The government has issued guidelines for the second phase of unlock ie Unlock 2. The new guidelines allow for more activities to be opened outside the containment zones. The new guidelines will be effective from 1 July 2020. The process of opening the economy in a phased manner has been taken forward. The new guidelines, are based on the feedback received from states and union territories and extensive consultation with the concerned central ministries and departments.